# Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

> **NCT01736943** · PHASE2 · COMPLETED · sponsor: **Joseph Tuscano** · enrollment: 25 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Doxil

## Key facts

- **NCT ID:** NCT01736943
- **Lead sponsor:** Joseph Tuscano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-19
- **Primary completion:** 2019-05-20
- **Final completion:** 2019-05-20
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01736943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01736943, "Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01736943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*